



Orphan Drug Report 2017

Quick facts and highlights



Download our Report
www.evaluategroup.com/orphandrug2017

Trends in Sales

Worldwide orphan drug sales forecast to be

\$209 Billion

Compound Annual Growth Rate for orphan drugs will be

2x overall drug market


Sales 2022



Orphan drugs will be 21.4% of worldwide prescription sales, excluding generics.

Leader Board: 2022

Sales	Celgene	Celgene set to climb to number 1 position in orphan drug sales in 2022
Drug	Revlimid (lenalidomide)	No.1 orphan drug in 2022
MVD	Axicabtagene Ciloleucel (Kite Pharma)	Most valuable R&D orphan drug



Average cost per patient per year 2016 (top 100 orphan and top 100 non-orphan drugs)



EvaluatePharma[®] estimates that the average cost per patient per year in 2016 for an orphan drug was **\$140,443** versus **\$27,756** for a non-orphan drug.

Per patient costs for orphan drugs is **5.5 times higher** than non-orphan drugs using median prices.

European pipeline forecast to be **56% orphan in 2022** growing with a **CAGR of +116%**.

Cost per patient is an estimate for the retail cost of a drug to a patient for a given year, based on a 100% compliance to the treatment guidelines outlined in the FDA label not including off-invoice discounts.



Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

EvaluatePharma[®] delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](https://twitter.com/EvaluatePharma)

EvaluateMedTech[®] sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](https://twitter.com/EvaluateMedTech)

EvaluateClinical Trials[®] delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](https://twitter.com/EPClinicalTrial)

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](https://twitter.com/EPVantage)

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate North America

EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109, USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate APAC

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052, Japan
T +81 (0)80 1164 4754